Journal of Thermal Analysis and Calorimetry

, Volume 134, Issue 3, pp 2041–2048 | Cite as

Thermal decomposition mechanism of piroxicam

  • Cheng-Jie Wu
  • Jin-Zong You
  • Xue-Jie Wang


Piroxicam (PRX) is a nonsteroidal anti-inflammatory drug. The thermal decomposition process of PRX was investigated with thermogravimetry and differential scanning calorimetry. The gaseous products generated by thermal decomposition were characterized with thermogravimetric analysis coupled with Fourier transform infrared spectroscopy. The residues of the thermal decomposition at various temperatures were identified with infrared spectroscopy. The molecular bond orders were calculated using an ab initio method from the GAMESS program of quantum chemistry. The mechanism of thermal decomposition for PRX was discussed. The results indicated that the thermal decomposition of PRX is a two-stage process with the initial temperature of 198 °C either in nitrogen or air atmospheres. The thermal decompositions of the first stage in two atmospheres are the same process. The main part of the molecule, including sulfamide, amide, benzene ring and pyridine ring, decompose simultaneously and to form gasifiable small molecules and carbonaceous residue in the first stage. The second stage in nitrogen is a slow thermal pyrolysis process of carbonaceous residue. The forepart of the second stage in air is a slow thermal pyrolysis process as like as in nitrogen, and the later period of the second stage is an oxidation (combustion) reaction process of carbonaceous residue. PRX is stable under ambient temperature and air atmosphere, and it can be preserved for long-term storage under ambient temperature and in air atmosphere.


Piroxicam (PRX) Thermal decomposition mechanism TGA–FTIR Quantum chemistry 


  1. 1.
    March L, Smith EU, Hoy DG, Cross MJ, Sanchez-Riera L, Blyth F, Buchbinder R, Vos T, Woolf AD. Burden of disability due to musculoskeletal (MSK) disorders. Best Pract Res Clin Rheumatol. 2014;28:353–66.CrossRefGoogle Scholar
  2. 2.
    Glyn-Jones S, Palmer AJ, Agricola R, Price AJ, Vincent TL, Weinans H, Carr AJ. Osteoarthritis. Lancet. 2015;386:376–87.CrossRefGoogle Scholar
  3. 3.
    Buckland-Wright C. Subchondral bone changes in hand and knee osteoarthritis detected by radiography. Osteoarthr Cartil. 2004;18:S10–9.CrossRefGoogle Scholar
  4. 4.
    Pelletier JP. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016;45:S22–7.CrossRefGoogle Scholar
  5. 5.
    Richardson CJ, Blocka KL, Ross SG, Verbeeck RK. Effects of age and sex on piroxicam disposition. Clin Pharmacol Ther. 1985;37:13–8.CrossRefGoogle Scholar
  6. 6.
    Eichstadt LR, Moore GE, Childress MO. Risk factors for treatment-related adverse events in cancer-bearing dogs receiving piroxicam. Vet Comp Oncol. 2017;15(4):1346–53.CrossRefGoogle Scholar
  7. 7.
    Kovala-Demertzi D. Recent advances on non-steroidal anti-inflammatory drugs, NSAIDs: organotin complexes of NSAIDs. J Organomet Chem. 2006;691:1767–74.CrossRefGoogle Scholar
  8. 8.
    Tita B, Stefanescu M, Tita D. Complex of anti-inflammatory non-steroidal drugs from oxicam family. 1. Synthesis and characterization of Zn (II) complex with Piroxicam. Rev Chim (Bucuresti). 2011;62(10):1002–7.Google Scholar
  9. 9.
    Dutta S, Padhye S, Mckee V. Structural characterization and SOD activity of copper–oxaprozinate. Inorg Chem Commun. 2004;7:1071–4.CrossRefGoogle Scholar
  10. 10.
    Ledeti A, Olariu T, Caunii A, Vlase G, Circioban D, Baul B, Ledeti I, Vlase T, Murariu M. Evaluation of thermal stability and kinetic of degradation for levodopa in non-isothermal conditions. J Therm Anal Calorim. 2018;131(2):1881–8.CrossRefGoogle Scholar
  11. 11.
    Cartaxo-Furtado NAD, de Castilho ARF, Freires IA, Santana CP, Sampaio TO, Xavier MA, de Medeiros ACD, Alves HD, Costa EMMD, Rosalen PL, Pereira JV. Physicochemical characterization of a new raw material obtained from leaves of Syzygium cumini (L.) Skeel (Myrtaceae). J Therm Anal Calorim. 2017;127(2):1137–41.CrossRefGoogle Scholar
  12. 12.
    Tak SR, Sohn YT. Crystal forms of a new 5-HT4 receptor agonist DA-6886. J Therm Anal Calorim. 2016;123(3):2477–83.CrossRefGoogle Scholar
  13. 13.
    Correa JCR, Perissinato AG, Serra CHD, Trevisan MG, Salgado HRN. Polymorphic stability of darunavir and its formulation. J Therm Anal Calorim. 2016;123(3):2185–90.CrossRefGoogle Scholar
  14. 14.
    Ledeti I, Bolintineanu S, Vlase G, Circioban D, Ledeti A, Vlase T, Suta LM, Caunii A, Murariu M. Compatibility study between antiparkinsonian drug Levodopa and excipients by FTIR spectroscopy, X-ray diffraction and thermal analysis. J Therm Anal Calorim. 2017;130(1):433–41.CrossRefGoogle Scholar
  15. 15.
    Attia AK, Mohamed GG, Ahmed HE. Structural investigation, molecular structure and molecular docking of solifenacin succinate, flavoxate hydrochloride and tolterodine tartrate anti-cholinergic drugs. J Therm Anal Calorim. 2018;131(2):1345–60.CrossRefGoogle Scholar
  16. 16.
    Jimenez JJ, Munoz BE, Sanchez MI, Pardo R. Forced and long-term degradation assays of tenoxicam, piroxicam and meloxicam in river water. Degradation products and adsorption to sediment. Chemosphere. 2018;191:903–10.CrossRefGoogle Scholar
  17. 17.
    Aminuddin M, Nazim U, Ahmad I. Photo- and thermal degradation of piroxicam in aqueous solution. Indian J Pharm Sci. 2012;73(4):387–91.Google Scholar
  18. 18.
    Modhave DT, Handa T, Shah RP, Singh S. Successful characterization of degradation products of drugs using LC–MS tools: application to piroxicam and meloxicam. Anal Methods. 2011;3(12):2864–72.CrossRefGoogle Scholar
  19. 19.
    Tiţa B, Marian E, Fuliaş A, Jurca T, Tiţa D. Thermal stability of piroxicam. J Therm Anal Calorim. 2013;112(1):367–74.CrossRefGoogle Scholar
  20. 20.
    Schmidt MW, Baldridge KK, Boatz JA, Elbert ST, Gordon MS, Jensen JJ, Koseki S, Matsunaga N, Nguyen KA, Su S, Windus TL, Dupuis M, Montgomery JA. General atomic and molecular electronic structure system. J Comput Chem. 1993;14:1347–63.CrossRefGoogle Scholar
  21. 21.
    Alexeev Y, Mazanetz MP, Ichihara O, Fedorov DG. GAMESS as a free quantum-mechanical platform for drug research. Curr Top Med Chem. 2012;12(18):2013–33.CrossRefGoogle Scholar
  22. 22.
    Xie JX, Chang JB, Wang XM. Applications of infrared spectroscopy in organic chemistry and medicinal chemistry. Beijing: Science Press; 2001 (in Chinese).Google Scholar
  23. 23.
    NIST Chemistry Web book Standard Reference Database, 2011, 69 release.
  24. 24.
    Wu CJ, You JZ, Wang XJ. Study on the thermal decomposition of famciclovir. J Therm Anal Calorim. 2018;131(2):1361–71.CrossRefGoogle Scholar
  25. 25.
    Gallo RC, Ferreira APG, Castro REA, Cavalheiro ETG. Studying the thermal decomposition of carvedilol by coupled TG–FTIR. J Therm Anal Calorim. 2016;123(3):2307–12.CrossRefGoogle Scholar
  26. 26.
    Mohamed GG, El-Sherif AA, Saad MA, El-Sawy SEA, Morgan SM. Mixed-ligand complex formation of tenoxicam drug with some transition metal ions in presence of valine: synthesis, characterization, molecular docking, potentiometric and evaluation of the humeral immune response of calves. J Mol Liq. 2016;223:1311–32.CrossRefGoogle Scholar
  27. 27.
    Raja MU, Tauchman J, Therrien B, Süss-Fink G, Riedel T, Dyson PJ. Arene ruthenium and pentamethylcyclopentadienyl rhodium and iridium complexes containing N, O-chelating ligands derived from piroxicam: synthesis, molecular structure and cytotoxicity. Inorg Chim Acta. 2014;409:479–83.CrossRefGoogle Scholar
  28. 28.
    de Souza KF, Martins JA, Pessine FB, Custodio R. A theoretical and spectroscopic study of conformational structures of piroxicam. Spectrochim Acta A. 2010;75(2):901–7.CrossRefGoogle Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2018

Authors and Affiliations

  1. 1.School of Science and TechnologyZhejiang International Studies UniversityHangzhouChina

Personalised recommendations